Institut Bergonié

LYON, France--(BUSINESS WIRE)-- Brenus Pharma announces that pre-clinical advancements of its inaugural research program were presented at the 7th CICON (International Cancer Immunotherapy) Conference in Milan, Italy (September 20-23) and will be showcased at the 38th Annual SITC (Society for Immunotherapy of Cancer) Congress in San Diego, CA, USA (November 1-5) These communications focus on pre-clinical validation of new developments of the first product generated by the STC Platform, STC-1010, which targets colorectal cancer in a first line of treatment. CONFERENCE TITLE AUTHORS RESULTS CICON23 P119: Allogenic Tumor Cell-Based Vaccine to Treat Colorectal Cancer: Development and Preclinical Validation George ALZEEB, Scientific Project Manager, Brenus Pharma, (Ph.D) Corinne TORTORELLI, Medical Lead, Brenus Pharma, (Pharm. D., Ph.D) Corentin RICHARD, Postdoc, Centre Georges-François Leclerc, ICMUB UMR CNRS 6302, (PhD) Romain BOIDOT, Molecular biologist, Centre Georges-François Leclerc, ICMUB UMR CNRS 6302, (PhD) Tanguy FORTIN, CEO, Anaquant, (PhD) Alban BESSEDE, CEO, Explicyte, (Ph.D) Yan WANG, R&D Project Manager, Inovotion, (M.D, PhD) Lionel CHALUS, LTO, Brenus Pharma Benoit PINTEUR, CSO, Brenus Pharma, (Pharm D) Paul BRAVETTI, CEO, Brenus Pharma, (Pharm D, MSc) Antoine ITALIANO, Early Phase Trials and Sarcoma Units, Institut Bergonie, (M.D, PhD) François GHIRINGHELLI, Director of UMR INSERM 1231, (MD,PhD) SEE POSTER SITC23 Stimulated Tumor Cells (STC) Vaccine Induce Response in Colorectal Cancer TO COME Benoit PINTEUR, (Pharm.D), Co-Founder and Chief Scientific Officer at Brenus Pharma explains: "After testing the STC product on colorectal cancer models in syngeneic immunocompetent mice (in vivo), where results have shown improved overall survival and enhanced immune response with STC-1010, we tested new models (ex vivo, in ovo) to enhance human extrapolation to validate the STC-1010 biological mechanism of action and replicate excellent results on human colorectal cancer models. All our efforts are now focused on regulatory approvals and batch production for the clinical trial in 2024." About STC Platform: "Stimulated-Tumor-Cells" is the first technology platform that generates cancer vaccines, based on cells that are stimulated to reproduce antigenic relapsing-tumor signatures; and haptenized to educate the immune system against resistant tumors. It breaks through current limitations by efficiently treating solid tumors, ensuring cost and supply control. For further information:

At the Annual Conference of the American Association for Cancer Research (AACR), in Orlando (Florida) from April 14th to 19th LYON, France--(BUSINESS WIRE)-- Brenus Pharma Announces two groundbreaking presentations on STC-1010, the company's first drug candidate for colorectal cancer (CRC), produced by Brenus Pharma's STC (Stimulated Tumor-Cells) Technology Platform. Innovative models for anti-tumor vaccine development were highlighted: Inovotion’s CAM (chorioallantoic model) in-ovo assay and Explicyte’s ex-vivo co-cultured assay, were used to characterize the mechanism of action through a specific immune response, and validate the anti-tumor effects of STC-1010. These models comply with the FDA’s modernization act 2.0 S. 5002 and demonstrate the potential of STC-1010 in clinical settings for the treatment of patients with colorectal cancer. The first study evaluated the safety and efficacy of STC-1010 in activating the antitumoral immune response against human colorectal adenocarcinoma using the chicken CAM assay. Results obtained in-ovo confirmed the anti-tumor efficacy -mediated by cytokine secretion and T cells expansion- of the vaccine previously observed in CRC syngeneic mouse models. Dendritic cells primed by STC-1010 will induce a multi specific pool of T-lymphocytes against the tumor without toxicity. The second study evaluated the functional activity of STC-1010-primed dendritic cells (DCs) from PBMCs human donors’ isolation, to activate autologous CD8+ T cells and promote tumor cell death. The study evaluated the cross-priming and specificity of the immune response induced by STC-1010. Results showed that STC-1010 is an efficient strategy to educate the immune system by cross-priming DCs and increasing the activity of specific CD8+ T cells (TCR sequencing) all of which promotes the significant tumor killing observed ex-vivo. Taken together, these studies provide promising results for the development of the STC-1010 and prove its potential to be presented into clinical setting for the treatment of patients with CRC. Innovative in vivo model for anti-tumor vaccine development: Safety validation and preliminary efficacy evaluation of a new antitumor vaccine STC-1010 on human colorectal adenocarcinoma using the chicken CAM assay. Session Title: Clinical Research Excluding Trials - Vaccines Abstract Presentation Number: 6791 Yan WANG, yan.wang@inovotion.com Scientist/R&D Project Manager2 (PhD) Arnaud PEYRONNIER, arnaud.peyronnier@inovotion.com, Sales Director4 (MSc) Benoit PINTEUR, bpinteur@brenus-pharma.com, Chief Scientific Officer3 (Pharm D) Lionel CHALUS, lchalus@brenus-pharma.com, Chief Scientific Officer5 Corinne TORTORELLI, ctortorelli@brenus-pharma.com, Medical Lead5 (Pharm. D., Ph.D) Paul BRAVETTI, pbravetti@brenus-pharma.com, Chief Executive Officer5 (Pharm D, MSc) Jean VIALLET, jean.viallet@inovotion.com, Chief Executive Officier4 (PhD) François GHIRINGHELLI FGhiringhelli@cgfl.fr, Head of Team Inserm 1231 TIRECs « Therapies and Immune REsponse in CancerS », Director of early clinical unit CLIPP2, Professor of Oncology4 (M.D, PhD) STC-1010 a new therapeutic vaccine promotes tumor cell death. Session Title: Late-Breaking Research: Immunology 2 Abstract Presentation Number: LB224 Alban BESSEDE, a.bessede@explicyte.com, Chief Executive Officer5 (Ph.D) George ALZEEB, galzeeb@brenus-pharma.com, Scientific Project Manager5 (Ph.D) Corinne TORTORELLI, ctortorelli@brenus-pharma.com, Medical Lead5 (Pharm.D., Ph.D) Jean-Philippe GUEGUAN, jp.gueguan@explicyte.com, Study Director7 Christophe REY, c.rey@explicyte.com7 Lionel CHALUS, lchalus@brenus-pharma.com, Chief Scientific Officer5 Benoit PINTEUR, bpinteur@brenus-pharma.com, Chief Scientific Officer5 (Pharm D) Paul BRAVETTI, pbravetti@brenus-pharma.com,Chief Executive Officer5(Pharm D, MSc) Antoine ITALIANO, a.italiano@bordeaux.unicancer.fr, Early Phase Trials and Sarcoma Units,6(M.D, Ph.D) For further information: 1 STC-1010 is a next-generation cancer vaccine immunotherapy that targets tumor antigens and is produced by Allogeneic STC's proprietary Brenus platform. It’s the lead candidate specifically designed to combat colorectal cancer (CRC) including MSS and MSI-H populations in its first line of treatment for the first indication. 2 Inovotion Biopolis- 5 av du Grand Sablon, 38700 La Tronche, France 3 Brenus Pharma Parc industriel Tech Lavaur La Bechade 63 500 Issoire, France 4 Center Georges François Leclerc, 1 rue du Pr Marion 21000 Dijon, France 5 Explicyte 229 Cours de l'Argonne, 33000 Bordeaux 6 Institut Bergonie 229 Cours de l'Argonne, 33000 Bordeaux

− Data presented at AACR Annual Meeting 2023 highlights the high unmet medical need for novel therapies to specifically address immune excluded tumors BOSTON--(BUSINESS WIRE)-- Parthenon Therapeutics, a precision oncology company discovering and developing a novel class of therapies that reprogram the tumor microenvironment (TME), today presented data at the AACR Annual Meeting 2023, on the high prevalence of immune exclusion in select solid tumor types. The data further support Parthenon’s planned Phase 1 clinical trial of lead candidate PRTH-101, a novel Discoidin Domain Receptor (DDR1) inhibitor which targets DDR1-directed collagen barriers in immune excluded tumors. (NCT05753722) This press release features multimedia. View the full release here: Patients with immune-infiltrated tumors have high levels of tumor-killing immune cells in contact with tumor cells and often respond to existing immunotherapies. However, most patients with solid tumors lack immune cells in physical proximity to tumor cells. This can be due to collagen barriers that prevent immune cells from reaching tumor cells in immune excluded tumors. DDR1 contributes to collagen barriers in the TME by aligning collagen fibers that prevent the infiltration of immune cells. “These data revealing the high incidence of immune exclusion in a number of cancer types demonstrate the large unmet need that exists in the field of immuno-oncology, which often does not address barriers in the TME that prevent immune cell interaction and killing of tumor cells,” said Laura Dillon, PhD, Vice President of Translational Medicine & Bioinformatics at Parthenon Therapeutics. The findings released today show that greater than 40% of patient tumors in triple negative breast cancer, non-small cell lung cancer, pancreatic ductal adenocarcinoma, and colorectal cancer are immune excluded based on both pathologist-defined immune phenotypes and image analysis. Moderate levels of immune exclusion were observed in ovarian cancer, and low levels in sarcoma subtypes. Furthermore, Parthenon proposed methodologies to systemically characterize immune phenotypes– based on the analyses of immunohistochemistry images, demonstrating both the benefits and limitations of this approach as benchmarked against more traditional methods for defining immune phenotypes that rely on pathologist impression. “There is a unique opportunity for PRTH-101 to address the largely neglected TME in patients with solid tumors. We look forward to providing updates in the coming months as we prepare to transition to a clinical stage company with the progression of our lead asset PRTH-101 into Phase 1 trials,” commented G. Travis Clifton, MD, co-founder, Head of Clinical Science at Parthenon Therapeutics. These data were generated in collaboration with Institute Bergonié (PI: Antoine Italiano). The poster detailing these findings - #2108 - will be presented at the American Association of Cancer Research (AACR) Annual Meeting on Monday, April 17, 2023. About PRTH-101 PRTH-101 is a therapeutic antibody that specifically binds to and blocks DDR1, a protein expressed on tumor cells that binds collagen to make a minimally permeable physical barrier that blocks immune cells from interacting with and attacking tumor cells. Thus, these “immune cell-excluded” solid tumors are resistant to attack by the immune system (as well as other existing therapies). By disabling DDR1, the collagen fibers lose alignment and loosen, creating gaps in the tumor barrier, thus allowing T-cells to enter and naturally attack the tumor. The creation of DDR1-directed collagen alignment does not appear to have a normal physiological surrogate and may therefore be unique to pathologies such as neoplasia, potentially allowing for relatively safe interventions. Thus, blockade of DDR1 represents a unique and “orthogonal” approach to stimulating the immune-based antitumor activity, and such blockade shows both single agent anti-tumor activity as well as marked augmentation of immunity enhanced by PD-1 blockade. Tumor types which show particularly high levels of DDR1-associated collagen barriers include colorectal, ovarian, and non-small cell lung cancer. Currently, there are no approved drugs that target DDR1. About Parthenon Therapeutics Parthenon Therapeutics is discovering and developing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME). Recent research has shown that the interplay of many cancers and their TME results in the creation of unique, non-physiologic barriers that markedly attenuate immune system attack. One approach utilized by PRTH-101 is to break down these barriers to overcome recalcitrant cancers. Based on rigorous, groundbreaking research, Parthenon is developing a portfolio of drug candidates to treat selected patients at the appropriate/ideal stage in disease progression. For more information visit parthenontx.com and LinkedIn.